Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.57 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.57 |
| ▸ | CASP1 | P29466 | 1/20 | 0.56 |
| ▸ | IL23R | Q5VWK5 | 9/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | TFPI | P10646 | 1/20 | 0.51 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29611501 | 0.96 | BACE1 (0.58) | BACE1BACE2CASP1IL23ROPRD1 | |
| SCHEMBL29611415 | 0.95 | BACE1 (0.59) | BACE1BACE2CASP1IL23ROPRD1 | |
| SCHEMBL29611561 | 0.94 | BACE1 (0.58) | BACE1BACE2CASP1IL23ROPRD1 | |
| SCHEMBL29611494 | 0.94 | BACE1 (0.58) | BACE1BACE2CASP1IL23RTFPI | |
| SCHEMBL29611329 | 0.94 | CASP1 (0.55) | BACE1BACE2CASP1IL23ROPRD1 | |
| SCHEMBL29611340 | 0.94 | TFPI (0.53) | BACE1BACE2CASP1IL23ROPRD1 | |
| SCHEMBL29611951 | 0.93 | BACE1 (0.54) | BACE1BACE2IL23RPTPN1TFPI | |
| SCHEMBL29611454 | 0.92 | PTPN1 (0.60) | BACE1BACE2CASP1IL23ROPRD1 | |
| SCHEMBL30918770 | 0.92 | IL23R (0.62) | IL23RTFPI | |
| SCHEMBL24739787 | 0.92 | CASP1 (0.53) | BACE1BACE2CASP1IL23ROPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12419824-B2 | Compounds useful for the treatment and/or care of the skin, hair, nails and/or mucous membranes | LUBRIZOL ADVANCED MATERIALS, INC. (US) | 2025-09-23 | — | — | US | claimed |
| US-20220183950-A1 | COMPOUNDS USEFUL FOR THE TREATMENT AND/OR CARE OF THE SKIN, HAIR, NAILS AND/OR MUCOUS MEMBRANES | LUBRIZOL ADVANCED MATERIALS, INC. (US) | 2022-06-16 | — | — | US | claimed |
| US-12419824-B2 | Compounds useful for the treatment and/or care of the skin, hair, nails and/or mucous membranes | LUBRIZOL ADVANCED MATERIALS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| EP-4573103-A1 | COMPOUNDS USEFUL FOR THE TREATMENT AND/OR CARE OF THE SKIN, HAIR, NAILS AND/OR MUCOUS MEMBRANES | Lubrizol Advanced Materials, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| WO-2024038345-A1 | COMPOUNDS USEFUL FOR THE TREATMENT AND/OR CARE OF THE SKIN, HAIR, NAILS AND/OR MUCOUS MEMBRANES | LUBRIZOL ADVANCED MATERIALS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| US-20220183950-A1 | COMPOUNDS USEFUL FOR THE TREATMENT AND/OR CARE OF THE SKIN, HAIR, NAILS AND/OR MUCOUS MEMBRANES | LUBRIZOL ADVANCED MATERIALS, INC. (US) | 2022-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220183950-A1 | COMPOUNDS USEFUL FOR THE TREATMENT AND/OR CARE OF THE SKIN, HAIR, NAILS AND/OR MUCOUS MEMBRANES | TYR, TELO2, MTX2 | BACE1 3288/4885BACE2 3110/4885CASP1 3410/4885 |
| US-12419824-B2 | Compounds useful for the treatment and/or care of the skin, hair, nails and/or mucous membranes | TYR, TELO2, MTX2 | BACE1 3288/4885BACE2 3110/4885CASP1 3410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.